Viatris And Biocon Line Up EU Bevacizumab
As Accord Receives Positive CHMP Opinion For Abiraterone
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
You may also be interested in...
Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.
With multiple US biosimilar applications held up by the FDA’s inability to conduct necessary inspections in the context of the COVID-19 pandemic, the agency tells Generics Bulletin that it is “actively working” on a solution.
Viatris has bounced back from withdrawing its application for a generic version of Gilenya in the EU with a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.